IL-10 Regulation of Lymphangiogenesis in Prostate Cancer
IL-10 Regulation of Lymphangiogenesis in Prostate Cancer
批准号:
7122505
负责人:
Mark E Stearns
金额:
$32.96万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-11-11 至 2009-02-28
关键词:
SCID mouseangiogenesisbiological signal transductioncell lineclinical researchcytokine receptorsenzyme linked immunosorbent assaygel mobility shift assaygene expressionhuman tissueinterleukin 10lymphopoiesismalemetastasisneoplasm /cancer diagnosisneoplasm /cancer geneticsneoplastic cellneoplastic processpathologic processpolymerase chain reactionprostate neoplasmstransfectionvascular endothelial growth factors
中文摘要
描述(由申请人提供):基于初步研究,我们假设IL-10/IL-10R轴控制“淋巴管生成开关”,导致微血管形成和肿瘤从“潜伏性癌症”转变为活跃生长的癌症,并表现出局部转移到神经周围纤维和淋巴结。在这项拨款申请中,总体目标是评估IL-10是否选择性地靶向淋巴管生成(和/或血管生成),以阻断原发性前列腺肿瘤亚群HPCA-10a、10b、10c、10d、10e和10f的微血管形成、前列腺肿瘤生长和局部转移。目标有三个,包括:目的1a:表征IL-10R轴信号通路,其下调VEGF D的合成;目的1b:探讨IL-10受体轴在原代肿瘤细胞系和肿瘤外植体中调控VEGF D/VEGF C表达的作用;目的:探讨IL-10对体外肿瘤细胞诱导的淋巴管生成(及血管生成)的影响。目标2。在原位SCID小鼠模型中检测IL-10转染是否阻断IL-10S1- VEGF D信号和VEGF D和VEGF C的表达以阻止淋巴管生成和/或血管生成,以及局部转移。目的3:通过免疫分析评估IL-10R轴调控的基因/蛋白的表达,这些基因/蛋白在人类前列腺肿瘤研究中与淋巴管生成(和血管生成)相关。标记研究将使用“组织阵列”块进行,这些块来自大约1294例前列腺癌标本和大约400例活组织切片(例如,包括过去5年收集的档案材料),以及整个前列腺的新鲜冷冻切片。我们将比较与假定的“潜伏性”癌症、恶性癌症以及局部转移到淋巴结、神经、肌肉和精囊的病理相关的表达谱。淋巴和微血管分布将通过LYVE-1、Podoplanin和Factor VIII抗体的免疫标记来测量。一个三维重建成像软件程序称为ACIS将用于测量微血管密度在连续切片。对5-10年期间的病理和患者预后数据的评估将允许评估基因表达谱的重要性。总的来说,这些研究应该证明IL-10R轴和下游效应基因(特别是IL-10S1-VEGF D和VEGF D)是否在淋巴管生成和/或血管生成过程中发挥关键作用。
英文摘要
DESCRIPTION (provided by applicant): We postulate, based on preliminary studies, that the IL-10/IL-10R axis controls a 'lymphangiogenesis switch' leading to microvessel formation and the transformation of tumors from 'latent cancers' to actively growing cancers, which exhibit localized metastases to the perineural fibers and lymph nodes.. In this grant application, the overall goal is to assess whether IL-10 selectively targets lymphangiogenesis (and/or angiogenesis) to block microvessel formation, prostate tumor growth and localized metastases by primary prostate tumor sublines, HPCA-10a, 10b, 10c, 10d, 10e and 10f. The goals are three foal, including: Aim 1a: to characterize the IL-10R axis signaling pathway, which down regulates VEGF D synthesis; Aim 1b: to evaluate the role of the IL-10 receptor axis in controlling VEGF D/VEGF C expression in primary tumor cell lines and tumor explants; Aim lc: to determine the influence of IL-10 on tumor cell induced lymphangiogenesis (and angiogenesis) in vitro. Aim 2. To test whether IL-10 transfection blocks IL-10S1- VEGF D signaling and VEGF D and VEGF C expression to prevent lymphangiogenesis and/or angiogenesis, and localized metastases in an orthotopic SCID mouse model. Aim 3: to evaluate the expression by immunoassays of the genes/proteins regulated by the IL-10R axis, which are associated with lymphangiogenesis (and angiogenesis) in human prostate tumor studies. The labeling studies will be done with 'tissue arrays' blocks generated from approximately 1294 prostate cancer specimens and approximately 400 biopsies (e.g. including archival material collected over the past 5 yrs), plus fresh frozen sections of whole mount prostates. We will compare the expression profiles relative to the pathology of putative 'latent' cancers, and malignant cancers as well as localized metastases to the lymph nodes, neural, muscle, and seminal vesicles. Lymphatic and blood microvessel distributions will be measured by immunolabeling with LYVE-1, Podoplanin and Factor VIII antibodies. A 3-D reconstruction imaging software program termed ACIS will be employed for measuring microvessel density in serial sections. Evaluation of the data with respect to the pathology and patient outcome over a 5-10 yr period will permit evaluation of the importance of gene expression profiles. Overall, the studies should demonstrate whether the IL-10R axis and down stream effector genes (and specifically IL-10S1-VEGF D, and VEGF D) play a pivotal role in lymphangiogenesis and/or angiogenesis processes.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
IL10 and IGF1 Receptor Axis in Prostate Cancer
-
批准号:6756456
-
项目类别:
-
资助金额:$28.2万
-
财政年份:2001
-
负责人:Mark E Stearns
-
依托单位:
IL10 and IGF1 Receptor Axis in Prostate Cancer
-
批准号:6318053
-
项目类别:
-
资助金额:$28.2万
-
财政年份:2001
-
负责人:Mark E Stearns
-
依托单位:
IL10 and IGF1 Receptor Axis in Prostate Cancer
-
批准号:6514956
-
项目类别:
-
资助金额:$28.2万
-
财政年份:2001
-
负责人:Mark E Stearns
-
依托单位:
IL10 and IGF1 Receptor Axis in Prostate Cancer
-
批准号:6895464
-
项目类别:
-
资助金额:$28.2万
-
财政年份:2001
-
负责人:Mark E Stearns
-
依托单位:
IL10 and IGF1 Receptor Axis in Prostate Cancer
-
批准号:6603132
-
项目类别:
-
资助金额:$28.2万
-
财政年份:2001
-
负责人:Mark E Stearns
-
依托单位:
IL-10 Regulation of Lymphangiogenesis in Prostate Cancer
-
批准号:7369898
-
项目类别:
-
资助金额:$32.0万
-
财政年份:1998
-
负责人:Mark E Stearns
-
依托单位:
IL-10 Regulation of Lymphangiogenesis in Prostate Cancer
-
批准号:6771264
-
项目类别:
-
资助金额:$33.75万
-
财政年份:1998
-
负责人:Mark E Stearns
-
依托单位:
IL-10 Regulation of Lymphangiogenesis in Prostate Cancer
-
批准号:6890003
-
项目类别:
-
资助金额:$33.75万
-
财政年份:1998
-
负责人:Mark E Stearns
-
依托单位:
IL-10 Regulation of Lymphangiogenesis in Prostate Cancer
-
批准号:7235661
-
项目类别:
-
资助金额:$32.0万
-
财政年份:1998
-
负责人:Mark E Stearns
-
依托单位:
TIMP-1 REGULATORY FACTORS IN HUMAN PROSTATE CANCER
-
批准号:6038404
-
项目类别:
-
资助金额:$15.55万
-
财政年份:1998
-
负责人:Mark E Stearns
-
依托单位:
TIMP-1 REGULATORY FACTORS IN HUMAN PROSTATE CANCER
-
批准号:2468755
-
项目类别:
-
资助金额:$13.88万
-
财政年份:1997
-
负责人:Mark E Stearns
-
依托单位:
TIMP-1 REGULATORY FACTORS IN HUMAN PROSTATE CANCER
-
批准号:2837794
-
项目类别:
-
资助金额:$29.9万
-
财政年份:1997
-
负责人:Mark E Stearns
-
依托单位:
TIMP-1 REGULATORY FACTORS IN HUMAN PROSTATE CANCER
-
批准号:6475926
-
项目类别:
-
资助金额:$31.36万
-
财政年份:1997
-
负责人:Mark E Stearns
-
依托单位:
IN VITRO SCREENING OF POTENTIAL CHEMOPREVENTIVE AGENTS
-
批准号:2602917
-
项目类别:
-
资助金额:$45.71万
-
财政年份:1997
-
负责人:Mark E Stearns
-
依托单位:
TIMP-1 REGULATORY FACTORS IN HUMAN PROSTATE CANCER
-
批准号:6124461
-
项目类别:
-
资助金额:$30.37万
-
财政年份:1997
-
负责人:Mark E Stearns
-
依托单位:
IN VITRO SCREENING OF POTENTIAL CHEMOPREVENTIVE AGENTS
-
批准号:6200439
-
项目类别:
-
资助金额:$0.0万
-
财政年份:1997
-
负责人:Mark E Stearns
-
依托单位:
CYTOGENETIC ANALYSIS OF HUMAN PROSTATE CANCER
-
批准号:3549862
-
项目类别:
-
资助金额:$23.43万
-
财政年份:1992
-
负责人:Mark E Stearns
-
依托单位:
CYTOGENETIC ANALYSIS OF HUMAN PROSTATE CANCER
-
批准号:2097944
-
项目类别:
-
资助金额:$32.07万
-
财政年份:1992
-
负责人:Mark E Stearns
-
依托单位:
CYTOGENETIC ANALYSIS OF HUMAN PROSTATE CANCER
-
批准号:3549863
-
项目类别:
-
资助金额:$29.66万
-
财政年份:1992
-
负责人:Mark E Stearns
-
依托单位:
CYTOGENETIC ANALYSIS OF HUMAN PROSTATE CANCER
-
批准号:2097943
-
项目类别:
-
资助金额:$29.66万
-
财政年份:1992
-
负责人:Mark E Stearns
-
依托单位:
国内基金
海外基金
登录
查看更多内容
RGD-68Ga@AuNCs PET监测PRMT5通过VEGFA调节肺腺癌血管新生的功能及机制
-
批准号:82372007
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:谢文晖
-
依托单位:
PROCR信号通路介导的血管新生在卵巢组织移植中的作用及机制研究
-
批准号:82371726
-
项目类别:面上项目
-
资助金额:50.00万元
-
批准年份:2023
-
负责人:李文
-
依托单位:
RNA编辑型IGFBP7在肿瘤细胞与肿瘤血管微环境中的调控作用及机制研究
-
批准号:32070790
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2020
-
负责人:徐小燕
-
依托单位:
ROBO4对视网膜血管生成(angiogenesis)的调控及其分子机制
-
批准号:81200692
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2012
-
负责人:陈凌
-
依托单位:
基于新生血管显像研究MSC治疗缺血性脑血管病的转化医学关键问题
-
批准号:81171370
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:朱朝晖
-
依托单位:
探索VASH2转录激活对肝细胞癌血管生成和上皮间质转化的作用及机制
-
批准号:81172267
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:高文涛
-
依托单位:
解析miR-566调控VHL/β-catenin信号通路影响人脑胶质瘤血管新生的分子机制
-
批准号:81101916
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:周旋
-
依托单位:
脂肪组织来源干细胞促进颗粒脂肪游离移植后再血管化机制的实验研究
-
批准号:81171834
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:鲁峰
-
依托单位:
99mTc-3PRGD2 SPECT显像用于评价肺癌抗新生血管药物疗效的动物研究及肺癌诊断临床研究
-
批准号:81171369
-
项目类别:面上项目
-
资助金额:56.0万元
-
批准年份:2011
-
负责人:李方
-
依托单位:
核素靶向示踪肿瘤新生血管作用位点研究
-
批准号:81071183
-
项目类别:面上项目
-
资助金额:32.0万元
-
批准年份:2010
-
负责人:王荣福
-
依托单位: